A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Exclusion Criteria

• •History of any clinically important disease or disorder
• •History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones
• •Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day
• •Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
• •Any clinically significant abnormal findings in vital signs
• •Any clinically significant abnormalities on 12-lead ECG
• •HbA1c ≥6.5% (≥48 mmol/mol)
• •Evidence of renal impairment
• •Females who are pregnant or lactating.
• •Any participant who has received an amylin analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer)
• •Participants who report to have previously received AZD6234.
• •Use of any prescribed or non-prescribed medication